A Population-Based Cohort Study on the Drug-Specific Effect of Statins on Sepsis Outcome

Chien Chang Lee, Meng tse Gabriel Lee, Tzu Chun Hsu, Lorenzo Porta, Shy Shin Chang, Chia Hung Yo, Kuang Chau Tsai, Matthew Lee

研究成果: 雜誌貢獻文章

5 引文 (Scopus)

摘要

Background: Whether statin treatment, proved by recent experimental studies to have an antimicrobial activity, exerts a drug- or a class-specific effect in sepsis remains unknown. Methods: Short-term mortality in patients with sepsis was analyzed using data from the National Health Insurance Research Database. Use of statins was defined as the cumulative use of a specific statin (atorvastatin, simvastatin, or rosuvastatin) for > 30 days prior to the index sepsis admission. We determined the association between statin and sepsis outcome by multivariate-adjusted Cox models and propensity score (PS)-matched analysis, using a 1:1:1 PS matching technique. Results: A total of 52,737 patients with sepsis fulfilled the inclusion criteria, of which 1,855 were prescribed atorvastatin, 916 were prescribed simvastatin, and 732 were prescribed rosuvastatin. Compared with nonusers, simvastatin (hazard ratio [HR], 0.72; 95% CI, 0.58-0.90) and atorvastatin (HR, 0.78; 95% CI, 0.68-0.90) were associated with an improved 30-day survival, whereas rosuvastatin was not (HR, 0.87; 95% CI, 0.73-1.04). Using rosuvastatin as the reference, atorvastatin (HR, 0.79; 95% CI, 0.64-0.99) and simvastatin (HR, 0.77; 95% CI, 0.59-0.99) had superior effectiveness in preventing mortality. Conclusions: Compatible with in vitro experimental findings, our results suggest that the drug-specific effect of statins on sepsis is not correlated to their lipid-lowering potency.

原文英語
頁(從 - 到)805-815
頁數11
期刊Chest
153
發行號4
DOIs
出版狀態已發佈 - 四月 1 2018

指紋

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Sepsis
Cohort Studies
Simvastatin
Pharmaceutical Preparations
Population
Propensity Score
Mortality
National Health Programs
Proportional Hazards Models
Databases
Lipids
Survival
Atorvastatin Calcium
Rosuvastatin Calcium
Research

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine
  • Cardiology and Cardiovascular Medicine

引用此文

Lee, C. C., Lee, M. T. G., Hsu, T. C., Porta, L., Chang, S. S., Yo, C. H., ... Lee, M. (2018). A Population-Based Cohort Study on the Drug-Specific Effect of Statins on Sepsis Outcome. Chest, 153(4), 805-815. https://doi.org/10.1016/j.chest.2017.09.024

A Population-Based Cohort Study on the Drug-Specific Effect of Statins on Sepsis Outcome. / Lee, Chien Chang; Lee, Meng tse Gabriel; Hsu, Tzu Chun; Porta, Lorenzo; Chang, Shy Shin; Yo, Chia Hung; Tsai, Kuang Chau; Lee, Matthew.

於: Chest, 卷 153, 編號 4, 01.04.2018, p. 805-815.

研究成果: 雜誌貢獻文章

Lee, CC, Lee, MTG, Hsu, TC, Porta, L, Chang, SS, Yo, CH, Tsai, KC & Lee, M 2018, 'A Population-Based Cohort Study on the Drug-Specific Effect of Statins on Sepsis Outcome', Chest, 卷 153, 編號 4, 頁 805-815. https://doi.org/10.1016/j.chest.2017.09.024
Lee, Chien Chang ; Lee, Meng tse Gabriel ; Hsu, Tzu Chun ; Porta, Lorenzo ; Chang, Shy Shin ; Yo, Chia Hung ; Tsai, Kuang Chau ; Lee, Matthew. / A Population-Based Cohort Study on the Drug-Specific Effect of Statins on Sepsis Outcome. 於: Chest. 2018 ; 卷 153, 編號 4. 頁 805-815.
@article{742ee67b93034be1914f481d0bc492be,
title = "A Population-Based Cohort Study on the Drug-Specific Effect of Statins on Sepsis Outcome",
abstract = "Background: Whether statin treatment, proved by recent experimental studies to have an antimicrobial activity, exerts a drug- or a class-specific effect in sepsis remains unknown. Methods: Short-term mortality in patients with sepsis was analyzed using data from the National Health Insurance Research Database. Use of statins was defined as the cumulative use of a specific statin (atorvastatin, simvastatin, or rosuvastatin) for > 30 days prior to the index sepsis admission. We determined the association between statin and sepsis outcome by multivariate-adjusted Cox models and propensity score (PS)-matched analysis, using a 1:1:1 PS matching technique. Results: A total of 52,737 patients with sepsis fulfilled the inclusion criteria, of which 1,855 were prescribed atorvastatin, 916 were prescribed simvastatin, and 732 were prescribed rosuvastatin. Compared with nonusers, simvastatin (hazard ratio [HR], 0.72; 95{\%} CI, 0.58-0.90) and atorvastatin (HR, 0.78; 95{\%} CI, 0.68-0.90) were associated with an improved 30-day survival, whereas rosuvastatin was not (HR, 0.87; 95{\%} CI, 0.73-1.04). Using rosuvastatin as the reference, atorvastatin (HR, 0.79; 95{\%} CI, 0.64-0.99) and simvastatin (HR, 0.77; 95{\%} CI, 0.59-0.99) had superior effectiveness in preventing mortality. Conclusions: Compatible with in vitro experimental findings, our results suggest that the drug-specific effect of statins on sepsis is not correlated to their lipid-lowering potency.",
keywords = "atorvastatin, rosuvastatin, sepsis, simvastatin, statin",
author = "Lee, {Chien Chang} and Lee, {Meng tse Gabriel} and Hsu, {Tzu Chun} and Lorenzo Porta and Chang, {Shy Shin} and Yo, {Chia Hung} and Tsai, {Kuang Chau} and Matthew Lee",
year = "2018",
month = "4",
day = "1",
doi = "10.1016/j.chest.2017.09.024",
language = "English",
volume = "153",
pages = "805--815",
journal = "Chest",
issn = "0012-3692",
publisher = "American College of Chest Physicians",
number = "4",

}

TY - JOUR

T1 - A Population-Based Cohort Study on the Drug-Specific Effect of Statins on Sepsis Outcome

AU - Lee, Chien Chang

AU - Lee, Meng tse Gabriel

AU - Hsu, Tzu Chun

AU - Porta, Lorenzo

AU - Chang, Shy Shin

AU - Yo, Chia Hung

AU - Tsai, Kuang Chau

AU - Lee, Matthew

PY - 2018/4/1

Y1 - 2018/4/1

N2 - Background: Whether statin treatment, proved by recent experimental studies to have an antimicrobial activity, exerts a drug- or a class-specific effect in sepsis remains unknown. Methods: Short-term mortality in patients with sepsis was analyzed using data from the National Health Insurance Research Database. Use of statins was defined as the cumulative use of a specific statin (atorvastatin, simvastatin, or rosuvastatin) for > 30 days prior to the index sepsis admission. We determined the association between statin and sepsis outcome by multivariate-adjusted Cox models and propensity score (PS)-matched analysis, using a 1:1:1 PS matching technique. Results: A total of 52,737 patients with sepsis fulfilled the inclusion criteria, of which 1,855 were prescribed atorvastatin, 916 were prescribed simvastatin, and 732 were prescribed rosuvastatin. Compared with nonusers, simvastatin (hazard ratio [HR], 0.72; 95% CI, 0.58-0.90) and atorvastatin (HR, 0.78; 95% CI, 0.68-0.90) were associated with an improved 30-day survival, whereas rosuvastatin was not (HR, 0.87; 95% CI, 0.73-1.04). Using rosuvastatin as the reference, atorvastatin (HR, 0.79; 95% CI, 0.64-0.99) and simvastatin (HR, 0.77; 95% CI, 0.59-0.99) had superior effectiveness in preventing mortality. Conclusions: Compatible with in vitro experimental findings, our results suggest that the drug-specific effect of statins on sepsis is not correlated to their lipid-lowering potency.

AB - Background: Whether statin treatment, proved by recent experimental studies to have an antimicrobial activity, exerts a drug- or a class-specific effect in sepsis remains unknown. Methods: Short-term mortality in patients with sepsis was analyzed using data from the National Health Insurance Research Database. Use of statins was defined as the cumulative use of a specific statin (atorvastatin, simvastatin, or rosuvastatin) for > 30 days prior to the index sepsis admission. We determined the association between statin and sepsis outcome by multivariate-adjusted Cox models and propensity score (PS)-matched analysis, using a 1:1:1 PS matching technique. Results: A total of 52,737 patients with sepsis fulfilled the inclusion criteria, of which 1,855 were prescribed atorvastatin, 916 were prescribed simvastatin, and 732 were prescribed rosuvastatin. Compared with nonusers, simvastatin (hazard ratio [HR], 0.72; 95% CI, 0.58-0.90) and atorvastatin (HR, 0.78; 95% CI, 0.68-0.90) were associated with an improved 30-day survival, whereas rosuvastatin was not (HR, 0.87; 95% CI, 0.73-1.04). Using rosuvastatin as the reference, atorvastatin (HR, 0.79; 95% CI, 0.64-0.99) and simvastatin (HR, 0.77; 95% CI, 0.59-0.99) had superior effectiveness in preventing mortality. Conclusions: Compatible with in vitro experimental findings, our results suggest that the drug-specific effect of statins on sepsis is not correlated to their lipid-lowering potency.

KW - atorvastatin

KW - rosuvastatin

KW - sepsis

KW - simvastatin

KW - statin

UR - http://www.scopus.com/inward/record.url?scp=85044128957&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044128957&partnerID=8YFLogxK

U2 - 10.1016/j.chest.2017.09.024

DO - 10.1016/j.chest.2017.09.024

M3 - Article

VL - 153

SP - 805

EP - 815

JO - Chest

JF - Chest

SN - 0012-3692

IS - 4

ER -